Narjust Florez, Assistant Professor of Medicine at Harvard Medical School, Co-Director Young Lung Cancer Program, Associate Director of the Cancer Access Program at Dana-Farber Cancer Institute, shared on LinkedIn:
“Molecular testing and immunotherapy are transforming cancer care, but patients also need to understand what these advances mean for them.
Our research highlights the importance of clearer, more consistent conversations in metastatic colorectal cancer care.
The science may be complex. The conversation doesn’t have to be.”
Title: Evaluating Oncologists’ Communication Strategies Regarding Molecular Testing and Immunotherapy
Authors: Meredith Gallagher, Samantha Vuong, Bonyan Qudah, Toby C. Campbell, Noelle K. LoConte, Narjust Florez, Michael Matthews, Jennifer M. Weiss, Monica Arun Patel
Read the full article.
You can also read AGEO-NEO-MSI Trial at ESMO GI: Neoadjuvant Immunotherapy Shows High Complete Response Rates in dMMR/MSI Colorectal Cancer on OncoDaily.
